September

Johann Farley, M.D.; Decision and Order (PDF) (September 29, 2026)

Angela Turner-Brown, N.P.; Decision and Order (PDF) (September 29, 2026)

Christopher Nadorff, M.D.; Decision and Order (PDF) (September 29, 2026)

Jorge J. Figueroa, M.D.; Decision and Order (PDF) (September 29, 2026)

JT Medical, LLC; Decision and Order (PDF) (September 29, 2026)

Cargill, Incorporated (PDF) (September 28, 2026)

Irvine Labs, Inc. (PDF) (September 28, 2026)

Benuvia Operations, LLC (PDF) (September 28, 2026)

Eli-Elsohly Laboratories (PDF) (September 24, 2026)

Cambridge Isotope Laboratories, Inc. (PDF) (September 24, 2026)

Cayman Chemical Company (PDF) (September 24, 2026)

Fisher Clinical Services, Inc. (I) (PDF) (September 24, 2026)

Cambridge Isotope Laboratories, Inc. (PDF) (September 24, 2026)

Proposed Rule: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I (PDF) (September 23, 2026)

60-Day Notice: Procurement Quota Certification and Recordkeeping Requirements (PDF) (September 23, 2026)

60-Day Notice: Application for Import Quota for Ephedrine, Pseudoephedrine, and Phenylpropanolamine (DEA Form 488) (PDF) (September 23, 2026)

60-Day Notice: Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine (DEA Form 250) (PDF) (September 23, 2026)

60-Day Notice: Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine (DEA Form 189) (PDF) (September 23, 2026)

Final Rule: Placement of Diphenidine in Schedule I (PDF) (September 21, 2026)

John Ramsay Walters, M.D.; Decision and Order (PDF) (September 21, 2026)

Esther Villanueva Valdes, M.D.; Decision and Order (PDF) (September 21, 2026)

Irvine Labs, Inc. (PDF) (September 14, 2026)

Cambrex High Point, Inc. (PDF) (September 14, 2026)

Craig Cohen, DPM; Decision and Order (PDF) (September 11, 2026)

Emran Mohammad, RN, APRN, CNP; Decision and Order (PDF) (September 11, 2026)

Cheryl White, N.P.; Decision and Order (PDF) (September 11, 2026)

Joseph John Stubbers III, D.O.; Decision and Order (PDF) (September 11, 2026)

Mark Allen, D.D.S.; Rescission of Final Agency Action and Withdrawal of Order To Show Cause (PDF) (September 8, 2026)

Stephen Bossenberry, M.D.; Decision and Order (PDF) (September 8, 2026)

Fresenius Kabi USA, LLC (PDF) (September 8, 2026)

Cambrex High Point, Inc. (PDF) (September 8, 2026)

Fisher Clinical Services, Inc. (PDF) (September 8, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (September 8, 2026)

Irvine Labs, Inc. (PDF) (September 8, 2026)

August

Leila Kump, M.D.; Decision and Order (PDF) (August 28, 2026)

Atlantic Treatment Center, LLC; Decision and Order (PDF) (August 28, 2026)

Thomas Earley, D.D.S.; Decision and Order (PDF) (August 28, 2026)

Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act (PDF) (August 27, 2026)

Interim Final Rule: Placement of Cipepofol in Schedule IV (PDF) (August 27, 2026)

Curia New York Inc. (PDF) (August 26, 2026)

Chemtos, LLC (PDF) (August 26, 2026)

Cambrex Charles City (PDF) (August 26, 2026)

Cambrex Charles City (PDF) (August 26, 2026)

Experic LLC (PDF) (August 26, 2026)

Catina Allen, N.P.; Decision and Order (PDF) (August 25, 2026)

Chattem Chemicals (PDF) (August 25, 2026)

Scottsdale Research Institute SRI Montana Satellite Laboratory (PDF) (August 25, 2026)

Biopharmaceutical Research Company (PDF) (August 25, 2026)

Curia New York Inc. (PDF) (August 25, 2026)

Prof Compounding CTS of Ameri (PDF) (August 25, 2026)

Galephar Pharmaceutical Research Inc. (PDF) (August 25, 2026)

Biopharmaceutical Research Company (PDF) (August 25, 2026)

Chattem Chemicals (PDF) (August 25, 2026)

Kinetochem LLC (PDF) (August 25, 2026)

Curia Missouri Inc. (PDF) (August 25, 2026)

Vici Health Sciences, LLC (PDF) (August 25, 2026)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (August 14, 2026)

Temporary Placement of O-Desmethyltramadol in Schedule I (PDF) (August 12, 2026)

Proposed Rule: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V (PDF) (August 11, 2026)

Proposed Rule: Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical (PDF) (August 3, 2026)

July

Joan Rubinger, N.P.; Decision and Order (PDF) (July 30, 2026)

60-Day Notice: Suspicious Orders of Controlled Substances (PDF) (July 29, 2026)

30-Day Notice: Medical History and Examination (PDF) (July 29, 2026)

Kerri Zavota, DVM; Decision and Order (PDF) (July 28, 2026)

Gene M. Koop, D.D.S.; Decision and Order (PDF) (July 28, 2026)

60-Day Notice: U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222 (PDF) (July 23, 2026)

60-Day Notice: Recordkeeping for the Transfer of Electronic Prescriptions in Schedules III-V between Pharmacies (PDF) (July 23, 2026)

60-Day Notice: Recordkeeping for Partial fills of Prescriptions (PDF) (July 23, 2026)

American Radiolabeled Chem (PDF) (July 23, 2026)

Cerilliant Corporation (PDF) (July 22, 2026)

Catalent Greenville, Inc. (PDF) (July 16, 2026)

AMPAC Fine Chemicals LLC (PDF) (July 16, 2026)

Unither Manufacturing LLC (PDF) (July 16, 2026)

Catalent CTS, LLC (PDF) (July 16, 2026)

Barlow St-Clair Lynch, M.D.; Decision and Order (PDF) (July 14, 2026)

David Enright, M.D.; Decision and Order (PDF) (July 14, 2026)

Shane Lydon, M.D.; Decision and Order (PDF) (July 14, 2026)

Frederick Tanzer, M.D.; Decision and Order (PDF) (July 10, 2026)

Timothy Genetta, D.O.; Decision and Order (PDF) (July 10, 2026)

Mark Allen, D.D.S.; Decision and Order (PDF) (July 10, 2026)

Ruth Jones, D.O.; Decision and Order (PDF) (July 10, 2026)

Mariana Moualem, F.N.P.; Decision and Order (PDF) (July 10, 2026)

Proposed Rule: Designation of Phenethyl Halides as List I Chemicals (PDF) (July 9, 2026)

Proposed Rule: Placement of Tianeptine in Schedule I (PDF) (July 8, 2026)

Benuvia Operations, LLC (PDF) (July 7, 2026)

Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (PDF) (July 6, 2026)

Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I (PDF) (July 6, 2026)

Proposed Amendment: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act (PDF) (July 1, 2026)

June

Almac Clinical Services Incorp. (ACSI) (PDF) (June 30, 2026)

Veranova, L.P. (PDF) (June 30, 2026)

Catalent Pharma Solutions, LLC (PDF) (June 30, 2026)

Veterans Pharmaceuticals, Inc. (PDF) (June 30, 2026)

United States Pharmacopeial Convention (PDF) (June 30, 2026)

Placement of Bromazolam in Schedule I; Correction (PDF) (June 24, 2026)

Temporary Placement of O-Desmethyltramadol in Schedule I (PDF) (June 24, 2026)

Amanda Ward, N.D.; Decision and Order (PDF) (June 24, 2026)

Irina Gross, D.P.M.; Decision and Order (PDF) (June 24, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (June 17, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (June 17, 2026)

Arizona Department of Corrections (PDF) (June 17, 2026)

Scottsdale Research Institute (PDF) (June 17, 2026)

Veranova, L.P. (PDF) (June 17, 2026)

Aphena Pharma Solutions MD, LLC (PDF) (June 17, 2026)

Wedgewood Pharmacy LLC (PDF) (June 17, 2026)

Cerilliant Corporation (PDF) (June 15, 2026)

VHG Labs DBA LGC Standards (PDF) (June 15, 2026)

Veranova, L.P. (PDF) (June 15, 2026)

Ashley Vermillion, N.P.; Decision and Order (PDF) (June 10, 2026)

Final Rule: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (PDF) (June 9, 2026)

CalCog Inc. (PDF) (June 8, 2026)

May

60-Day Notice: Student Volunteer Service Agreement (PDF) (May 28, 2026)

Proposed Rule: Placement of Diphenidine in Schedule I (PDF) (May 26, 2026)

Proposed Rule: Removal of Exemption Status for Inactive Butalbital Products (PDF) (May 26, 2026)

Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I (PDF) (May 22, 2026)

Final Rule: Authority of Drug Enforcement Administration Supervisory Diversion Investigators, Field Intelligence Managers, and Intelligence Group Supervisors To Sign and Issue Administrative Subpoenas (PDF) (May 21, 2026)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (May 20, 2026)

Proposed Rule: Revision of Applications for Manufacturing and Procurement Quotas (PDF) (May 20, 2026)

Organix Chemistry Solutions LLC (PDF) (May 20, 2026)

Amneal Pharmaceuticals, LLC (PDF) (May 20, 2026)

Benuvia Operations, LLC (PDF) (May 18, 2026)

Final Rule: Placement of CUMYL-PEGACLONE in Schedule I (PDF) (May 13, 2026)

Final Rule: Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance (PDF) (May 4, 2026)

ANI Pharmaceuticals Inc. (PDF) (May 4, 2026)

Patheon API Inc. (PDF) (May 4, 2026)

ANI Pharmaceuticals Inc. (PDF) (May 4, 2026)

Patheon Pharmaceuticals Inc. (PDF) (May 4, 2026)

Final Rule: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (PDF) (May 1, 2026)